Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Down 14.4% in October

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 192,800 shares, a decrease of 14.4% from the October 15th total of 225,200 shares. Based on an average daily volume of 24,700 shares, the short-interest ratio is presently 7.8 days. Currently, 3.2% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AYTU. Dimensional Fund Advisors LP raised its position in shares of Aytu BioPharma by 54.5% during the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock worth $69,000 after acquiring an additional 8,311 shares during the last quarter. Stonepine Capital Management LLC increased its position in Aytu BioPharma by 6.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after purchasing an additional 28,489 shares during the period. Finally, Armistice Capital LLC bought a new position in Aytu BioPharma during the 2nd quarter worth approximately $736,000. 33.49% of the stock is owned by institutional investors.

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $1.58 on Friday. The stock has a 50-day moving average price of $2.21 and a two-hundred day moving average price of $2.61. Aytu BioPharma has a 12 month low of $1.49 and a 12 month high of $3.45. The company has a market capitalization of $9.72 million, a PE ratio of -1.28 and a beta of -1.40. The company has a current ratio of 0.99, a quick ratio of 0.79 and a debt-to-equity ratio of 0.39.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.78% and a negative net margin of 8.28%. The business had revenue of $17.98 million for the quarter.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.